Chris Shibutani
Stock Analyst at Goldman Sachs
(3.47)
# 799
Out of 4,792 analysts
99
Total ratings
51.92%
Success rate
0.63%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $30.18 | +231.35% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.24 | +142.91% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $1 → $0.75 | $0.71 | +4.98% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $31.78 | +0.69% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $91.96 | +48.99% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $12.42 | +165.70% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $306.70 | -1.53% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $31.74 | +60.68% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $160.21 | -3.25% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $3.52 | +13.80% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $14.44 | +38.55% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $789.14 | -8.38% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $18.98 | +37.02% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $103.10 | +48.40% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $202.54 | -14.58% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.59 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $58.31 | +18.33% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $18.09 | -28.12% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $32.93 | -30.15% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.01 | +4,875.12% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $24.05 | +116.22% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.37 | +146.20% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $8.11 | +122.09% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.29 | +1,222.96% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.06 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.75 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.91 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.13 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $30.18
Upside: +231.35%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.24
Upside: +142.91%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $1 → $0.75
Current: $0.71
Upside: +4.98%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $31.78
Upside: +0.69%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $91.96
Upside: +48.99%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $12.42
Upside: +165.70%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $306.70
Upside: -1.53%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $31.74
Upside: +60.68%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $160.21
Upside: -3.25%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $3.52
Upside: +13.80%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $14.44
Upside: +38.55%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $789.14
Upside: -8.38%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $18.98
Upside: +37.02%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $103.10
Upside: +48.40%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $202.54
Upside: -14.58%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.59
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $58.31
Upside: +18.33%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $18.09
Upside: -28.12%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $32.93
Upside: -30.15%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.01
Upside: +4,875.12%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $24.05
Upside: +116.22%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.37
Upside: +146.20%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $8.11
Upside: +122.09%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $1.29
Upside: +1,222.96%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.06
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.75
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $29.13
Upside: -